ASTRAZENECA PLC ANNOUNCES TAGRISSO MET PRIMARY ENDPOINT IN PHASE III 2ND-LINE LUNG CANCER TRIAL

Tagrisso demonstrated superior progression-free survival compared to standard
platinum-based chemotherapy, with a safety profile consistent with previous
trials

First randomised trial to evaluate the clinical benefit of an EGFR T790M
medicine, and data are consistent with those supporting Tagrisso approvals
This announcement contains inside information

AstraZeneca today announced that the Phase III AURA3 trial met its primary
endpoint, demonstrating superior progression-free survival (PFS) compared to
standard platinum-based doublet chemotherapy. The AURA3 randomised trial
assessed the efficacy and safety of Tagrisso as a 2nd-line treatment in more
than 400 patients with EGFR T790M mutation-positive, locally-advanced or
metastatic NSCLC, whose disease had progressed following 1st-line EGFR tyrosine
kinase inhibitor (TKI) therapy. Tagrisso also demonstrated a safety profile
consistent with previous trials.

In addition to PFS, the objective response rate (ORR), disease control rate
(DCR) and duration of response (DoR) also achieved clinically meaningful
improvement versus chemotherapy. A full evaluation of AURA3 data, including an
analysis of overall survival (OS), is ongoing, and results will be presented at
an upcoming medical meeting.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief
Medical Officer at AstraZeneca, said: "These results confirm Tagrisso as a
meaningful alternative to benefit EGFR T790M lung cancer patients. The AURA3
results demonstrate the benefits of our science-led approach that enabled the
rapid development of Tagrisso as a targeted treatment to address the most common
cause of resistance to a first-generation EGFR-TKI　for patients with metastatic
EGFR-mutant lung cancer. We remain committed to exploring the potential of
Tagrisso to further extend its reach and help meet patient need."

Tagrisso is one of the fastest development programmes ever, from start of
clinical trials to approval in just over two and a half years. It was approved
in the US, EU, Japan, Canada, Switzerland, Israel and Mexico　as the first
treatment for patients with EGFR T790M mutation-positive advanced NSCLC.
Tagrisso is also approved in South Korea in the same indication. Eligibility for
treatment with Tagrisso is dependent on confirmation that the EGFR T790M
mutation is present in the tumour.

AstraZeneca is committed to exploring the full potential of Tagrisso as
monotherapy and in combination, for patients with lung cancer, including in
adjuvant and locally-advanced/ metastatic 1st-line EGFRm settings. In addition,
AstraZeneca is exploring Tagrisso in NSCLC patients with and without brain
metastases, and has presented encouraging data in a small cohort of patients
with leptomeningeal disease.

About Non-Small Cell Lung Cancer (NSCLC)

Lung cancer is the leading cause of cancer death among both men and women,
accounting for about one-third of all cancer deaths and more than breast,
prostate and colorectal cancers combined. Patients who have the EGFRm form of
NSCLC, which occurs in 10-15% of NSCLC patients in the US and Europe and 30-40%
of NSCLC patients in Asia, are particularly sensitive to treatment with
currently-available EGFR-TKIs, which block the cell signalling pathways that
drive the growth of tumour cells. However, tumours almost always develop
resistance to treatment, leading to disease progression. In approximately two
-thirds of patients treated with approved EGFR-TKIs such as gefitinib and
erlotinib, this resistance is caused by the secondary mutation, T790M.

About Tagrisso

Tagrisso (osimertinib, AZD9291) 80mg once-daily tablet is the first medicine
indicated for the treatment of adult patients with locally-advanced or
metastatic EGFR T790M mutation-positive NSCLC. Tagrisso is as an irreversible
EGFR inhibitor, born out of scientific exploration and engineered to combat the
mechanism of resistance by targeting the T790M resistance mutation.

Tagrisso is also being investigated in the adjuvant and metastatic 1st-line
settings, including in patients with and without brain metastases, in
leptomeningeal disease, and in combination with other treatments.

About AURA3

AURA3 compared the efficacy and safety of Tagrisso 80mg once daily and platinum
-based doublet chemotherapy in 419 patients with EGFR T790M mutation-positive,
locally-advanced or metastatic NSCLC whose disease had progressed on or after
treatment with a previous EGFR-TKI. The trial was carried out in more than 130
locations worldwide, including the USA, Canada, Europe, China, Japan, Korea,
Taiwan and Australia.

The primary endpoint of the trial was PFS, and secondary endpoints included OS,
ORR, DoR, DCR, safety and measures of health-related quality of life (HRQoL).

About AstraZeneca in Oncology

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing
portfolio of new medicines that has the potential to transform patients' lives
and the Company's future. With at least 6 new medicines to be launched between
2014 and 2020, and a broad pipeline of small molecules and biologics in
development, we are committed to advance New Oncology as one of AstraZeneca's
six Growth Platforms focused on lung, ovarian, breast and blood cancers. In
addition to our core capabilities, we actively pursue innovative partnerships
and investments that accelerate the delivery of our strategy as illustrated by
our investment in Acerta Pharma in haematology.

By harnessing the power of four scientific platforms -- immuno-oncology, the
genetic drivers of cancer and resistance, DNA damage response and antibody drug
conjugates --　and by championing the development of personalised combinations,
AstraZeneca has the vision to redefine cancer treatment and one day eliminate
cancer as a cause of death.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on
the discovery, development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas - Respiratory and
Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company
is also active in inflammation, infection and neuroscience through numerous
collaborations. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Neil Burrows         UK/Global                              +44 203 749 5637
Vanessa Rhodes       UK/Global                              +44 203 749 5736
Karen Birmingham     UK/Global                              +44 203 749 5634
Rob Skelding         UK/Global                              +44 203 749 5821
Jacob Lund           Sweden                                 +46 8 553 260 20
Michele Meixell      US                                     +1 302 885 2677
Investor Relations
UK
Thomas Kudsk Larsen                                         +44 203 749 5712
Craig Marks          Finance, Fixed Income, M&A             +44 7881 615 764
Nick Stone           Respiratory and Autoimmunity           +44 203 749 5716
Henry Wheeler        Oncology                               +44 203 749 5797
Christer Gruvris     Infection and Neuroscience             +44 203 749 5711
US
Lindsey Trickett     Cardiovascular and Metabolic Diseases  +1 240 543 7970
Mitchell Chan        Oncology                               +1 240 477 3771
Toll-free                                                   +1 866 381 7277

Adrian Kemp
Company Secretary
AstraZeneca PLC

-ENDS-